Author | Dwaine Rieves, MD

Articles

Eltrombopag for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura

December 01, 2009

On November 20, 2008, the US Food and Drug Administration (FDA) granted accelerated approval for eltrombopag (Promacta Tablets, GlaxoSmithKline) for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulin therapy, or splenectomy.

Romiplostim for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura

July 14, 2009

On August 22, 2008, the US Food and Drug Administration (FDA) granted marketing approval (licensure) to romiplostim (Nplate, Amgen Inc) for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.

Deferasirox for the Treatment of Chronic Iron Overload in Transfusional Hemosiderosis

December 01, 2006

This report describes the Food and Drug Administration's review of data and analyses leading to the approval of the oral iron chelator, deferasirox for the treatment of chronic iron overload due to transfusional hemosiderosis.